Heart-type Fatty Acid Binding Protein (H-FABP) IT Assay

The Heart-type Fatty Acid Binding Protein (H-FABP) assay from Randox is a rapid, accurate immunoturbidimetric assay for the quantitative determination of H-FABP in serum and plasma. Suitable for use on the RX Series of chemistry analysers, results can be obtained in less than 14 minutes. Applications are also available for a wide range of analysers.

H-FABP is 20 times more cardiac specific than Myoglobin and is released as early as 30 minutes after an ischemic episode, providing rapid diagnosis when it is critically needed.  

Key Features and Benefits

• Identify Troponin-negative ACS patients who are at long term risk of death
• Identify a very high risk group of patients who warrant further investigation and possible intervention
• Addition of H-FABP to Troponin measurements could avoid unnecessary investigations caused by false positives
• Highly sensitive - <2.5 ng/ml
• Linearity up to 120.0 ng/ml

TxB Cardio IT Assay

TxB Cardio is an immunoturbidimetric assay providing accurate and rapid analysis of 11-dehydro thromboxane B2 (11-dhTXB₂) levels in urine.  The assay evaluates aspirin effect in apparently healthy individuals post ingestion based on the levels of the thromboxane metabolite in a random urine sample.  Levels exceeding the therapeutic cut off of 1500pg/mg are indicative of a lack of aspirin effect or aspirin resistance.

In aspirin treated patients, studies have shown correlation between high levels of 11-dhTXB₂ and increased risk of myocardial infarction and cardiac death. Up to 25% of patients on aspirin therapy receive no benefit with aspirin resistant patients having an approximate four fold increased risk of cardiovascular events.

The Randox TxB Cardio assay is a fully automated assay providing quantitative determination of thromboxane levels in just ten minutes.  

Key Features and benefits

• TxB Cardio assesses aspirin treatment effectiveness and enables clinicians to optimise therapy
• The assay can identify aspirin resistance and associated potential cardiac risk
• Non invasive and easy to use method of analysis
• Urine based assay avoids associated complications of in-vitro platelet activation during blood collection
• Fully automated applications available for the RX series and a wide range of clinical analysers